What question did this study set out to answer?

The aim is to propose an ethical framework for decision-making around Alzheimer’s disease biomarker testing in clinical settings.

February 21, 2026npj DementiaOpen Access

An ethical framework for the clinical use of Alzheimer’s disease biomarker testing

View Full Paper

Ask AI

Bookmark

The aim is to propose an ethical framework for decision-making around Alzheimer’s disease biomarker testing in clinical settings.
Developed by a multidisciplinary team
Grounded in current evidence and ethical principles
Illustrated using real-world case scenarios
Addresses clinical benefit and patient values
Considers risks involved in biomarker testing
Highlights future research needs for ethical implementation

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

An ethical framework guides decision-making for using blood-based biomarkers in Alzheimer's disease, implying significant implications for primary care.

Cite This Study

Scipion et al. (2026) studied this question.

synapsesocial.com/papers/69994c14873532290d020403 https://doi.org/10.1038/s44400-026-00060-4

View Full Paper

Ask AI

Bookmark

Implication

An ethical framework guides decision-making for using blood-based biomarkers in Alzheimer's disease, implying significant implications for primary care.

An ethical framework for the clinical use of Alzheimer’s disease biomarker testing

Key Points

Discussion

Implication

Cite This Study

An ethical framework for the clinical use of Alzheimer’s disease biomarker testing

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider